A Phase 2 Randomized, Placebo-Controlled, Double-Blind Study of Carboplatin/Paclitaxel in Combination With ABT-869 Versus Carboplatin/Paclitaxel Alone in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) as First-Line Treatment

Inclusion Criteria:

- Subject must be at least 18 years of age.

- Subject must have cytologically or histologically confirmed non-squamous NSCLC

- Subject must have recurrent or advanced (Stage IIIb with pleural or pericardial
effusion) or metastatic (Stage IV) disease that is not amenable to surgical resection
or radiation with curative intent.

- Subject has measurable disease, defined as at least 1 unidimensional measurable
lesion on a computed tomography (CT) scan as defined by RECIST (for subjects in the
randomized portion only).

- Subject has an ECOG Performance Score of 0-1.

- Willing to take adequate measures to prevent pregnancy.

Exclusion Criteria:

- The subject has NSCLC with a predominant squamous cell histology

- Subject has hypersensitivity to paclitaxel.

- Subject has received any anti-cancer therapy for treatment of NSCLC.

- Subject has received radiation therapy within 21 days of Study Day 1.

- Subject has had major surgery within 21 days.

- Subject has untreated brain or meningeal metastases.

- Subject is receiving therapeutic anticoagulation therapy.

- Subject has a central thoracic tumor lesion as defined by location within the hilar
structures.

- Subject has proteinuria CTC Grade > 1 at baseline.

- Subject has a history of, or currently exhibits clinically significant cancer related
events of bleeding.

- The subject currently exhibits symptomatic or persistent, uncontrolled hypertension
defined as diastolic blood pressure (BP) > 90 mm Hg or systolic BP > 140 mm Hg.

- The subject has a history of myocardial infarction, stroke or Transient Ischemic
Attack (TIA) within 6 months of Study Day 1.

- The subject has a documented left ventricular (LV) ejection fraction < 50%.

- The subject has known autoimmune disease with renal involvement (i.e., lupus).

- The subject is receiving combination anti-retroviral therapy for HIV.

- The subject has clinically significant uncontrolled condition(s).

- The subject has a history of another active cancer within the past 5 years.

- The subject has active ulcerative colitis, Crohn's disease, celiac disease or any
other conditions that interfere with absorption.

- The subject has a medical condition, which in the opinion of the study investigator
places them at an unacceptably high risk for toxicities.

- The subject is pregnant or breast feeding.